Monday, July 29, 2024
10:00 AM ET
Virtual KOL Event to Discuss Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG8) Conference
International Stroke Conference 2025
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and cardio-renal disease.
DiaMedica Therapeutics, Inc.
301 Carlson Parkway
Suite 210
Minneapolis, MN 55305
DiaMedica Therapeutics Inc.
Scott Kellen
Chief Financial Officer
T: (763) 496-5192
F: (763) 710-4456
skellen@diamedica.com